Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications

Stopped early · Phase 2

Conditions studied: Psoriasis

In brief

The purpose of this study is to determine the efficacy for Bicillin L-A, administered intramuscularly in a dose of 2.4 million units every three (3) weeks, for the treatment of chronic, plaque-type psoriasis unresponsive to topical medications or when other systemic therapies are contraindicated.

Key facts

Study ID

NCT00427609

Run by

University of Tennessee

People needed

5

Starts

2007-01-01

Expected to finish

2009-11-01

Last updated by the study team

2015-04-21

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female between 18 and 50 years of age (with onset before age 40)
• Presence of chronic plaque type psoriasis unresponsive to treatment with topical preparations and extensive enough to consider appropriateness of systemic therapy
• Guttate forms of psoriasis
• Non-responsive to treatment or worsening of the pre-existing psoriasis
• With the exception of their skin disease , in good general state of health based on a complete medical history, blood test and urine analysis.
• Females must have negative urine pregnancy test and willing to take additional measures to keep from becoming pregnant during the course of the study
• No systemic prescription medication to control psoriasis within past 30 days
• Free of any topical antipsoriatic preparation for the duration of the study with the exception of emollients and moisturizers

You may not qualify if…

• Pustular forms of psoriasis, either localized or generalized
• Generalized Erythrodermic psoriasis
• Only palmoplantar psoriasis
• Only scalp psoriasis
• Only nail psoriasis
• Only inverse psoriasis
• Diabetes or impaired glucose tolerance
• History of recurrent yeast infections
• History of hypersensitivity to Penicillin
• History of severe adverse drug reactions
• Pregnancy
• Lactation
• HIV/AIDS
• History of renal disease
• History of liver disease
• History or presence of alcohol and/or drug dependence or abuse
• History of significant psychiatric illness
• History of allergy, asthma, allergic rhinitis, or urticaria subjects in other research trials, at least 30 days prior to the beginning of this study

Where it is running

• University of Tennessee Health Science Center — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.